- Home
- NTIC vs TCRX Comparison
NTIC vs TCRX Comparison
Compare NTIC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIC
- TCRX
- Stock Information
- Founded
- NTIC 1970
- TCRX 2018
- Country
- NTIC United States
- TCRX United States
- Employees
- NTIC N/A
- TCRX N/A
- Industry
- NTIC Industrial Specialties
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- NTIC Industrials
- TCRX Health Care
- Exchange
- NTIC Nasdaq
- TCRX Nasdaq
- Market Cap
- NTIC 71.5M
- TCRX 82.1M
- IPO Year
- NTIC N/A
- TCRX 2021
- Fundamental
- Price
- NTIC $8.47
- TCRX $1.51
- Analyst Decision
- NTIC Buy
- TCRX Strong Buy
- Analyst Count
- NTIC 1
- TCRX 6
- Target Price
- NTIC $20.00
- TCRX $9.50
- AVG Volume (30 Days)
- NTIC 84.2K
- TCRX 664.0K
- Earning Date
- NTIC 07-10-2025
- TCRX 08-11-2025
- Dividend Yield
- NTIC 3.44%
- TCRX N/A
- EPS Growth
- NTIC N/A
- TCRX N/A
- EPS
- NTIC 0.38
- TCRX N/A
- Revenue
- NTIC $84,445,763.00
- TCRX $4,421,000.00
- Revenue This Year
- NTIC $2.05
- TCRX $159.20
- Revenue Next Year
- NTIC $4.70
- TCRX N/A
- P/E Ratio
- NTIC $21.30
- TCRX N/A
- Revenue Growth
- NTIC 2.11
- TCRX N/A
- 52 Week Low
- NTIC $6.75
- TCRX $1.02
- 52 Week High
- NTIC $16.75
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- NTIC 61.95
- TCRX 50.74
- Support Level
- NTIC $7.37
- TCRX $1.39
- Resistance Level
- NTIC $8.43
- TCRX $1.73
- Average True Range (ATR)
- NTIC 0.34
- TCRX 0.13
- MACD
- NTIC 0.10
- TCRX -0.01
- Stochastic Oscillator
- NTIC 73.03
- TCRX 38.24
About NTIC Northern Technologies International Corporation
Northern Technologies International Corp, or NTIC is a United States-based firm that develops and markets environmentally beneficial products and services world-wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.